7 results about "Entry into host cell" patented technology

This invention relates to the field of pharmaceutical technology, disclosing a method for inhibiting Zika virus and its application. The invention identifies CD104 as the binding receptor for Zika virus and demonstrates that CD104 participates in Zika virus invasion of host cells, assisting in the virus's entry into host cells. Therefore, CD104 can provide a new and important target for the development of drugs that inhibit Zika virus invasion. Thus, this invention provides the application of a specific inhibitor of the Zika virus receptor CD104 protein in the preparation of drugs for the prevention or treatment of diseases caused by Zika virus infection.

The invention discloses an antiviral composite particle as well as a screening method and application thereof. A polymer reversible hydrogen bond network with hydrophilicity and hydrophobicity is utilized, the coordination mode of the metal oligomer is precisely regulated and controlled, the dispersity and virus capturing capacity of the material are balanced by regulating charge distribution of a polymer main chain, and an electrostatic barrier is formed on the surface of the material by regulating surface potential, so that the virus capturing effect is improved. Therefore, the material selectively adsorbs virus particles without entering host cells, and intracellular toxicity is avoided. Besides, through controllable assembly of the metal oligomer and collaborative design of polymer interface engineering, the tradeoff of'activity-toxicity 'of a traditional metal-based material is broken through, and powerful support is provided for development of broad-spectrum and safe antiviral drugs, coatings, protective equipment and the like.

The present disclosure relates to a C-based single domain antibody that neutralizes respiratory syncytial virus (RSV) and its application thereof. The C-based single domain antibody of the present disclosure is a neutralizing antibody against RSV F protein, can inhibit the viral entry into host cells, and can be used for the prevention, treatment and diagnosis of RSV, as well as for further studying the mechanism of RSV infection. The C-based single domain antibody has a smaller molecular weight, better tissue permeability and the ability to bind to antigenic epitope with steric hindrance effect; it can be expressed in multiple expression systems, including prokaryotic, yeast, and mammalian cells. The C-based single domain antibody has a low production cost and a short production cycle; it has a wide range of administration routes and can be administered through nasal drops, nasal spray, spray, aerosol inhalation, intramuscular injection, intravenous injection, subcutaneous injection, etc.

This invention provides a chimeric adenovirus vector Ad5F35 and a recombinant CCR5-32 mutant gene, its construction method, and its application, belonging to the field of gene therapy technology. The construction method provided by this invention includes the following steps: (1) inserting the CCR5Δ32 mutant gene into the multiple cloning site of a shuttle vector to obtain a shuttle plasmid; (2) co-transfecting cells with the shuttle plasmid and the Ad5F35 adenovirus backbone plasmid to generate an Ad5F35 chimeric recombinant adenovirus capable of expressing the CCR5Δ32 gene. By inducing the inability of the CCR5 protein on the host cell to be normally expressed on the cell membrane surface, the binding of HIV-1 gp 120 to the CCR5Δ32 mutant gene is effectively prevented, thus preventing the HIV-1 virus from entering the host cell for replication, thereby achieving the goal of treating AIDS.

The application provides application of PLX8394 in preparation of an anti-ZIKV drug, a structural formula of the PLX8394 is shown as formula 1, the application firstly finds that the PLX8394 can be used for treating infectious diseases caused by ZIKV, and experiments show that the PLX8394 has extremely strong antiviral activity on ZIKV, can significantly inhibit replication of ZIKV on host cells A549, improve cell survival rate, can inhibit the process of virus entering the host cells A549, and has extremely strong antiviral effect at a cell level, and has obvious anti-ZIKV effect.

The application discloses an antiviral composite particle and a screening method and application thereof. The application utilizes a polymer reversible hydrogen bond network with hydrophilicity and hydrophobicity, precisely regulates a coordination mode of a metal oligomer, balances material dispersibility and virus capturing capacity by adjusting a charge distribution of a polymer main chain, and controls a material surface to form an electrostatic barrier through a surface potential, so that the material selectively adsorbs virus particles without entering host cells, and cell toxicity is avoided. In addition, through the synergistic design of controllable assembly of the metal oligomer and polymer interface engineering, the application breaks through the dilemma of the trade-off between "activity-toxicity" of traditional metal-based materials, and provides strong support for the development of broad-spectrum, safe antiviral drugs, coatings, protective equipment and the like.

The invention discloses an application of a Fascin protein inhibitor in virus infection resistance. Specifically, the invention discloses an application of a small molecule drug NP-G2-044, and the small molecule drug NP-G2-044 is used for preparing a drug preparation or a composition for resisting virus infection. According to the NP-G2-044 disclosed by the invention, the formation of filopodia clamped by a virus is inhibited, so that the novel coronavirus is prevented from entering a host cell through the filopodia, and the virus infection is effectively controlled.